Cost Effectiveness of Treatment of Parkinson's Disease with Entacapone in the United States

ISSN： 1170-7690

Source： PharmacoEconomics, Vol.20, Iss.9, 2002-09, pp. : 617-628

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Treatment of Advanced Parkinson's Disease in the United States: A Cost-Utility Model

By Groenendaal Huybert

Clinical Drug Investigation, Vol. 30, Iss. 11, 2010-11 ,pp. : 789-798

Adis International

Access to resources Recommend Favorite

Cost-Effectiveness Analysis of Dopamine Agonists in the Treatment of Parkinson's Disease in Japan

By Shimbo T.

PharmacoEconomics, Vol. 19, Iss. 8, 2001-01 ,pp. : 875-886

Adis International

Access to resources Recommend Favorite

Entacapone in the management of Parkinson’s disease

By Waters Cheryl Henchcliffe Claire

Expert Opinion on Pharmacotherapy, Vol. 3, Iss. 7, 2002-07 ,pp. : 957-963

Informa Healthcare

Access to resources Recommend Favorite

Cost Effectiveness of Pharmacotherapies in Early Parkinson's Disease

By Eggert Karla M. Reese Jens P. Oertel Wolfgang H. Dodel Richard

CNS Drugs, Vol. 22, Iss. 10, 2008-01 ,pp. : 841-860

Adis International

Access to resources Recommend Favorite

Cost Effectiveness of Pramipexole in Parkinson's Disease in the US

By Hoerger T.J.

PharmacoEconomics, Vol. 14, Iss. 5, 1998-11 ,pp. : 541-557

Adis International

Access to resources Recommend Favorite